Drug Trial Radar · NCT01099774
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
597
Actual
Start
May 1, 2010
Primary completion
Apr 29, 2011
Study completion Apr 29, 2011
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
Bimatoprost 0.03% Formulation B Ophthalmic SolutionDrug
One drop administered in each eye, every evening, for 12 weeks
Bimatoprost 0.03% Ophthalmic SolutionDrug
One drop administered in each eye, every evening, for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12Time frame: Baseline, Week 12
- Average Eye IOP at Week 12Time frame: Baseline, Week 12
- Average Eye IOP at Week 6Time frame: Week 6
- Average Eye IOP at Week 2Time frame: Week 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.